Placebo News and Research

RSS

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

25 Feb 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours.

24 Feb 2016

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).

24 Feb 2016

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.

23 Feb 2016

Dapivirine ring can help prevent HIV-1 infection in women

In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.

23 Feb 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

MRI for unwitnessed stroke looking promising

Results of the MR WITNESS study suggest that magnetic resonance imaging may be able to identify patients with strokes that can be treated with tissue plasminogen activator, even if the time of symptom onset is unknown.

22 Feb 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved opioid-induced constipation (OIC) compared to placebo in patients with chronic non-cancer pain.

22 Feb 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

19 Feb 2016

FDA-approved Alzheimer's medications may help people quit smoking

Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt. University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.

19 Feb 2016

Tackling insulin resistance may reduce recurrence after stroke

Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial.

18 Feb 2016

More phase II success for CGRP migraine prevention strategy

Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.

18 Feb 2016

Testosterone treatment for older men improves sexual function, walking ability and mood

As men age, their testosterone levels decrease, but prior studies of the effects of administering testosterone to older men have been inconclusive. Now, research shows that testosterone treatment for men over 65 improves sexual function, walking ability and mood, according to a study published in the New England Journal of Medicine by team researchers from the Perelman School of Medicine at the University of Pennsylvania, and twelve other medical centers in the United States, in partnership with the National Institute on Aging.

18 Feb 2016

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.

18 Feb 2016

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

17 Feb 2016

Study: Many school children avoid basic foods due to perceived hypersensitivity

A study on hypersensitivity to the basic foods milk, egg, fish and wheat among young school children showed that reported food hypersensitivity was eight times more common than allergies confirmed by allergy tests. This according to a new dissertation at Umeå University.

17 Feb 2016

Experimental vaccine shows effectiveness in Ebola vaccine trial

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus.

16 Feb 2016

Placebo News and Research

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

New clinical trial launched to test potential drug that could help immune system combat cancer

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Dapivirine ring can help prevent HIV-1 infection in women

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

MRI for unwitnessed stroke looking promising

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

FDA-approved Alzheimer's medications may help people quit smoking

Tackling insulin resistance may reduce recurrence after stroke

More phase II success for CGRP migraine prevention strategy

Testosterone treatment for older men improves sexual function, walking ability and mood

Pioglitazone drug may prevent recurrent stroke and heart attacks

Promising phase II results for ozanimod in MS

Study: Many school children avoid basic foods due to perceived hypersensitivity

Experimental vaccine shows effectiveness in Ebola vaccine trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News